

Remarks


By the present amendment, applicants have cancelled Claims 17, 19, and 23-24, and amended Claim 21 to correct a typographical error. In addition, applicants have amended the claims to eliminate multiple dependencies. No new matter has been added. Therefore, the claims remaining for consideration by the Examiner are Claims 1-16, 18, and 20-22.

The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(609) 627-8507

  
\_\_\_\_\_  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

Date: September 29, 2006